Qilian International Holding Group (Qilian International Holding Group) Change In Working Capital : $1.11 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Qilian International Holding Group Change In Working Capital?

Qilian International Holding Group's change in working capital for the quarter that ended in Sep. 2023 was $2.54 Mil.

Qilian International Holding Group's change in working capital for the fiscal year that ended in Sep. 2023 was $1.11 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Qilian International Holding Group Change In Working Capital Historical Data

The historical data trend for Qilian International Holding Group's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qilian International Holding Group Change In Working Capital Chart

Qilian International Holding Group Annual Data

Trend

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Working Capital

Get a 7-Day Free Trial

-7.70

-0.79

-3.67

8.75

1.11

Qilian International Holding Group Semi-Annual Data
	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Change In Working Capital	Get a 7-Day Free Trial								-10.18	2.46	6.29	-1.42	2.54

Qilian International Holding Group Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.11 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Qilian International Holding Group Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Qilian International Holding Group's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Qilian International Holding Group (Qilian International Holding Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Qilian International Holding Group Ltd (NAS:QLI) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Jiuquan Economic and Technological Development Zone, Gansu Province, Jiuquan, CHN, 735000

Website

http://ir.qlsyy.net

Qilian International Holding Group Ltd is a pharmaceutical and chemical company. The company is engaged in the development, manufacture, marketing, and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers. It operates through three segments namely, Oxytetracycline and Licorice products and TCMD; Fertilizer; and Heparin products and Sausage casing. Oxytetracycline and Licorice products and TCMD segment generates majority of the revenue.